Golden State Wealth Management LLC Takes $107,000 Position in Aligos Therapeutics, Inc. (NASDAQ:ALGS)

Golden State Wealth Management LLC bought a new position in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 2,674 shares of the company’s stock, valued at approximately $107,000. Golden State Wealth Management LLC owned approximately 0.07% of Aligos Therapeutics as of its most recent SEC filing.

Separately, Drive Wealth Management LLC acquired a new position in shares of Aligos Therapeutics in the fourth quarter valued at $916,000. Institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Stock Up 0.1 %

NASDAQ ALGS opened at $27.53 on Monday. Aligos Therapeutics, Inc. has a twelve month low of $6.76 and a twelve month high of $46.80. The stock has a market cap of $98.83 million, a P/E ratio of -2.07 and a beta of 2.45. The company’s 50-day simple moving average is $33.10 and its 200 day simple moving average is $19.68.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Aligos Therapeutics in a report on Thursday, November 7th.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).